Poor
Mostly Aligned
Patient Risk:
Low
Summary
The submitted content does not provide a single verifiable AI-generated claim to check against the FDA label sentences. As a result, support status for each subcomponent cannot be confirmed line-by-line; only general topic alignment is inferable.
Category Scores
Accurate Statements
Serious, life-threatening, or fatal respiratory depression is reported with codeine (an active ingredient in TUXARIN ER).
Supported by provided label excerpt in section 5.2 (Life-Threatening Respiratory Depression): 'Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, including codeine...'
Drug interaction warnings include benzodiazepines/CNS depressants/alcohol increasing risk of profound sedation/respiratory depression/coma/death.
Supported by provided label excerpt in section 5.9 and 7.5 (e.g., 'Avoid use... may result in... profound sedation, respiratory depression, coma, and death.' and 'Avoid the use of TUXARIN ER...')
Drug interaction warnings include CYP3A4 inhibitors/inducers and CYP2D6 inhibitors potentially increasing codeine/morphine exposure and increasing/prolonging adverse reactions including potentially fatal respiratory depression.
Supported by provided label excerpt in section 5.8 and 7.1/7.2/7.4 (e.g., 'may result in... greater morphine levels... potentially fatal respiratory depression' and 'may cause serious/potentially fatal respiratory depression').
Unsupported Statements
The AI claim that the risk is 'greatest during initiation' and that this is part of the FDA label support for TUXARIN ER (as phrased in the AI response).
Cannot be verified as an exact statement from the AI-generated response because the prompt did not include the exact AI output sentences to map line-by-line. Although the label excerpt in section 5.2 includes 'the risk is greatest during the initiation of therapy,' verification requires matching the exact AI wording/scope.
The AI claim that there is 'increased risk in children' including 'accidental ingestion by children.'
Cannot be verified line-by-line against the AI response because exact AI sentences were not provided. While label excerpts support pediatric risk and accidental ingestion ('Accidental ingestion of even one dose of TUXARIN ER, especially by children... can result in respiratory depression and death'), confirmation that the AI statement precisely matches the label scope/wording is not possible from the provided text.
The AI claim that medication errors/overdosage contribute to the risk (as phrased in the AI response).
Not verifiable as an exact AI phrasing match because the AI response text is not available as a single claim sentence for auditing. Although label excerpt 5.6/2.1 support 'Dosing errors can result in accidental overdose and death' and 'Advise patients not to increase the dose... serious adverse events such as respiratory depression may occur with overdosage,' matching the AI statement precisely cannot be confirmed.
Contradictions
Important Omissions
No evaluation of contraindication details (e.g., 'contraindicated in all children younger than 12 years of age' and 'post-operative management after tonsillectomy/adenoidectomy under 18') can be confirmed because the provided text does not include the exact AI statements to assess whether these were included or omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The content provided is consistent in topic with multiple label warnings regarding respiratory depression, pediatric risk, medication errors/overdosage, and avoidance with benzodiazepines/CNS depressants and certain CYP-modulating drugs. However, the lack of exact AI-claim text prevents confirmation of precise wording and scope, limiting confidence rather than indicating a direct contradiction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
The audit cannot reliably map the AI-generated claim to the label because the exact AI response sentences were not provided for verification; only topic areas were inferable.
Suggested Improvement
Provide the exact single/sentences from the AI-generated response to be evaluated (verbatim), then re-audit against the corresponding FDA label sentences (e.g., the 'risk is greatest during the initiation of therapy' and pediatric/accidental ingestion sentences).